Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst ELEMENT-- Back to the Newsroom Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical ...

Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that Babar K. Rao, MD, FAAD, an internationally recognized academ ...

Core Insights - Medicus Pharma has reported promising data from its Phase 2 clinical trial for SkinJect, a non-invasive treatment for basal cell carcinoma, indicating a potential reduction in the need for surgical interventions [1][3][5] Company Updates - The CEO of Medicus Pharma, Raza Bokhari, expressed excitement over the Phase 2 dataset, which shows that approximately 75% of treated patients may not require Mohs surgery, addressing a significant unmet medical need [3][5] - The clinical trial demonstrated a 73% clinical or visual clearance rate at day 57 for the 200 microgram cohort following excisional biopsy, which is considered very promising by clinicians [4][9] Industry Context - There are nearly 5 million new cases of basal cell carcinoma diagnosed annually in the U.S., with a backlog of over a million procedures due to a shortage of trained Mohs surgeons, highlighting the urgent need for effective treatments [4] - The microneedle technology used in SkinJect is patent protected and shows biological activity, especially when loaded with doxorubicin, enhancing clinical outcomes [6][8] Regulatory and Future Plans - Medicus Pharma is preparing for an end-of-Phase 2 meeting with the FDA to discuss the design of a pivotal study, with expectations to submit a request by mid-2023 [5][10] - The company aims to secure a strategic partner for co-development of the therapy, which could potentially lead to a blockbuster product [9][10]

Core Insights - Medicus Pharma Ltd. will participate in the Longwood Miami CEO Forum, focusing on its AI-enabled drug development strategy aimed at enhancing clinical trial efficiency [1][2] - The company is actively engaged in developing innovative therapeutics, including a non-invasive treatment for basal cell skin cancer and a next-generation GnRH antagonist for prostate cancer [1][2] Company Participation and Events - Dr. Raza Bokhari, Executive Chairman & CEO, will be part of a panel titled "Accelerating the Path to Patient Care" at the Longwood Miami CEO Forum on March 12-13, 2026 [1] - The event will feature notable industry leaders and aims to foster discussions on healthcare innovation [1] Strategic Collaborations and Developments - Medicus has entered a non-binding memorandum of understanding with Helix Nanotechnologies to explore joint development opportunities in mRNA technology [1][2] - The company completed the acquisition of Antev, focusing on a new treatment for advanced prostate cancer, which may improve patient compliance and outcomes [1][2] Clinical Trials and Regulatory Approvals - The company has received regulatory approvals in the UK for its Phase 2 clinical study evaluating D-MNA for treating basal cell carcinoma [2] - Medicus has successfully enrolled 90 patients in the U.S. for the same study and anticipates an end-of-Phase 2 meeting with the FDA in the first half of 2026 [2] Future Plans and Innovations - Medicus plans to collaborate with Reliant AI Inc. to develop an AI-driven clinical data analytics platform to enhance clinical trial efficiency [2] - The company has received FDA clearance to initiate a Phase 2b dose-optimization study of Teverelix for advanced prostate cancer [2]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

The Company Reported 73% Clinical Clearance in the 200-µg cohort at Day 57PHILADELPHIA, March 09, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today provided additional context regarding the recently reported topline dataset from the Phase 2 SKNJCT-003 study evaluating SkinJect® microneedle delivery of D-MNA and P-MNA for ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists, ensuring independent content production [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

Core Insights - Oracle is facing significant financial pressure due to its ambitious cloud expansion plans, particularly in AI infrastructure, which has led to job cuts and hiring freezes [2][3][7] Company Overview - Oracle has transitioned from being a distant third in cloud computing to a key player after securing major contracts with OpenAI, xAI, and Meta, which require substantial investment in data centers [4][5] - The company has revised its capital expenditure for fiscal 2026 to $50 billion, significantly higher than the previous estimate of $35 billion, indicating a need for rapid infrastructure build-out [6] Workforce Impact - Oracle is preparing to cut thousands of jobs across various divisions, with some layoffs expected imminently, reflecting a broader strategy to manage cash flow pressures [3][8] - The layoffs are not limited to underperforming units but are widespread, with some roles being eliminated due to anticipated AI advancements that may render them redundant [8] Customer and Market Implications - Major cloud customers like OpenAI, xAI, and Meta are at risk if Oracle's financial instability affects its ability to fulfill contracts, particularly as they have structured their infrastructure around Oracle's capabilities [9] - Competing cloud providers such as AWS, Microsoft Azure, and Google Cloud may benefit from Oracle's challenges, as enterprise customers may reconsider their reliance on Oracle amid concerns about its stability [11][12] Industry Dynamics - Oracle's situation highlights a broader issue in the AI infrastructure sector, where the need for large capital investments can outpace revenue generation, raising questions about the sustainability of such business models [13][16] - The trend of job cuts in the tech industry, justified by AI investments, is becoming more common, reinforcing the perception that certain job categories are at risk due to technological advancements [14] Financial Considerations - Oracle is expected to report third-quarter earnings amid heavy debt issuance and rising capital expenditures, with analysts closely monitoring how the company plans to manage its debt load while continuing to invest [10][16] - The company's ability to justify its significant investments in AI cloud contracts will depend on the growth and profitability of AI cloud demand [16][17]

Core Insights - Medicus Pharma Ltd. shares experienced volatility, peaking at $1.61 before declining during premarket trading following the release of Phase 2 clinical trial data for SKNJCT-003 [1] - The Phase 2 study demonstrated a 73% clinical clearance rate for Doxorubicin Microneedle Array (D-MNA) in treating basal cell carcinoma (BCC), which may facilitate an end-of-phase meeting with the FDA in the first half of 2026 [2][3] Clinical Trial Results - The topline results from the SKNJCT-003 Phase 2 clinical study indicated a 73% clinical clearance rate and a 40% histological clearance rate from a 200µg dose cohort [3] - The study involved 90 patients diagnosed with nodular basal cell carcinoma, providing decision-grade evidence of clinical activity [3] Future Plans - The company plans to compile a comprehensive Clinical Study Report by the second quarter of 2026, which will include full safety analyses and procedural observations [4] Stock Performance - Medicus Pharma's stock is currently trading 8.70% above its 20-day simple moving average (SMA) but is 12.5% below its 100-day SMA, indicating short-term strength and longer-term challenges [5] - Over the past 12 months, shares have significantly decreased and are closer to their 52-week lows than highs, with the current price at $1.09 during premarket trading [5][7] Technical Analysis - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [6] - The combination of neutral RSI and bearish MACD indicates mixed momentum, prompting traders to monitor potential shifts in momentum [6]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for being a forward-looking technology adopter, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]